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In here presented in silico study we suggest a way how to implement the evolutionary principles
into anti-cancer therapy design. We hypothesize that instead of its ongoing supervised adaptation,
the therapy may be constructed as a self-sustaining evolutionary process in a dynamic fitness land-
scape established implicitly by evolving cancer cells, microenvironment and the therapy itself. For
these purposes, we replace a unified therapy with the ‘therapy species’, which is a population of
heterogeneous elementary therapies, and propose a way how to turn the toxicity of the elementary
therapy into its fitness in a way conforming to evolutionary causation. As a result, not only the thera-
pies govern the evolution of different cell phenotypes, but the cells’ resistances govern the evolution
of the therapies as well. We illustrate the approach by the minimalistic ad hoc evolutionary model.
Its results indicate that the resistant cells could bias the evolution towards more toxic elementary
therapies by inhibiting the less toxic ones. As the evolutionary causation of cancer drug resistance
has been intensively studied for a few decades, we refer to cancer as a special case to illustrate purely
theoretical analysis.
I. INTRODUCTION
Development of up-to-date anti-cancer therapies re-
lies on the deep knowledge of specific biochemical
machinery of cancer cells. However, despite im-
proved understanding of the molecular details of can-
cer initiation and progression, many targeted thera-
pies fail due to diversity of strategies of resistance
deployed by cancer cells [1–4]. Presently, intratu-
mor heterogeneity is viewed as the principal obsta-
cle in the therapy design and many papers have re-
viewed its causes and consequences to therapeutic re-
sistance during the last decades [5–12]. The mecha-
nisms of resistance relate to altered activity of the spe-
cific enzyme systems, blocked apoptosis, developing
transport mechanisms which provide multidrug re-
sistance, etc. It was demonstrated that clonal that ac-
cumulation of the viable clonal genetic variants poses
greater threat of progressing to cancer than the ho-
mogenizing clonal expansion [13]. Moreover, it is
known for a long time that the epigenetic changes,
such as DNA methylation, histone modifications,
chromatin remodeling, and small RNA molecules,
play the causative role in cancer initiation, progres-
sion [14–16] and resistance [17]. Considering the
timescales during which mutations spread in a can-
cer cell population, the contribution of non-genetic
instability in the intratumor heterogeneity of cancer
cell populations is significant [18].
Another obstacle to efficient therapies consists in a
static manner of the administration of most thera-
pies which underestimates that many properties of
cancer cells that contribute to the invasion, metas-
tases and resistance likely arise as successful adap-
tive strategies to survive and proliferate within the
temporally unstable micro-environmental conditions
[19], induced, eventually, by the therapy itself. It was
shown that the adaptive therapeutic intervention that
reflects the temporal and spatial variability of the tu-
mor microenvironment and cellular phenotype may
provide substantially longer survival than the stan-
dard high dose density strategies [20].
Evolutionary Dynamics of Cancer. Since Now-
ell conceptualized carcinogenesis as the evolutionary
process [21], evolutionary theory has been accepted
as the appropriate conceptual base to get an insight
into the modus operandi of cancer [21–23]. Evolution-
ary dynamics, in which the intratumor heterogene-
ity plays the crucial role, equips evolving populations
of neoplastic cells with the adaptive power enabling
them to cope with uncertain or time-varying micro-
environmental conditions and it is considered as the
main reason why the targeted therapy of cancer fails
[24], and why the combination therapy, despite often
improved therapeutic outcome, is still not the ulti-
mate winner in the fight against cancer [25]. Nowa-
days, an effort to address the heterogeneity and vari-
ability of cancer cells in the therapy design is appar-
ent [26, 27].
Therapeutic resilience of advanced cancers may be at-
tributed not only to genetic diversity but to epigenetic
plasticity as well [28]. A major difference between the
epigenetic and genetic changes is that the epigenetic
changes are reversible and, in principle, responsive
to environmental influence. Variability in the pheno-
typic characteristics of isogenic cells confers to cellu-
lar tissues important properties, such as the ability of
cancer cells to escape a targeted therapy by switch-
2ing to an alternative phenotype [29, 30]. It motivates
an effort to stimulate (or prevent) the specific pheno-
type switching purposefully as a therapeutic strategy
[31, 32].
The interplay between the respective genomes, epi-
genomes, transcriptomes and proteomes constitutes
a ’cell-state’ [33]. Due to their tendency to be self-
stabilizing, there are typically fewer distinct cell
states in a tumor than it could be inferred from the
degree of the genetic, epigenetic and transcriptional
heterogeneity and, straightforwardly, genetically dis-
tinct cells may be susceptible to the treatment with
the same drugs [34]. On the other hand, even ge-
netically identical cells can, due to the epigenetic dif-
ferences and influence of an microenvironment, ex-
ist in different cell states. Studying the cell-state dy-
namics of the isogenic population of human breast
cancer cells revealed that the three phenotypic frac-
tions (stem, basal and luminal) stay under the fixed
genetic and environmental conditions in the equilib-
rium proportions and that individual cells transition
from one state to another with constant interconver-
sion rates [35]. Moreover, if the fractions were pur-
posely deviated from the equilibrium, the equilib-
rium proportions were reestablished by interconver-
sions between the cell states instead of differential
growth of the respective phenotypic subpopulations.
Therefore, Markov process was proposed as the ap-
propriate mathematical model for the respective cell-
state dynamics [35].
Presuming that the cells in different states differ in
their growth properties, the cell-state composition of
the cancer cell population becomes evolutionary im-
portant trait at the cancer-relevant timescales dur-
ing which the cancer cells are exposed, in general,
to changing environment (including the therapy). In
this case, the population may benefit from maintain-
ing the diversity of cell states, each advantageous
within a different context [36, 37]. It was observed
that in the case of variable selective pressure, the
population of different organisms evolves the mecha-
nisms to tune the phenotypic variability of the pop-
ulation to reflect the variability of the acting selec-
tive pressure [38]. In bacteria, the well known risk-
diversification strategy evolved in populations when
facing changing environment [39–41] is bet-hedging
[42, 43]. This strategy increases the long-term sur-
vival and growth of an entire lineage instead of con-
ferring an immediate fitness benefit to one individual
[36]. Based on the formal similarity of evolving can-
cer cell population with bacteria, viruses or yeast, it
has been recently proposed that the structure of in-
tratumor heterogeneity is an evolutionary trait which
evolves towards the maximum clonal fitness at the
cancer-relevant timescale in changing (or uncertain)
environment and that its structure corresponds to the
bet-hedging strategy [44–47] which has been recently
put into therapeutic context [48].
Distinguishing between the intratumor heterogene-
ity due to the differences in the DNA sequences and
that resulting from the epigenetic modifications is in-
structive for the biological insight as well as for the
’physical’ realization of an eventual therapy. Nev-
ertheless, as the genetic and epigenetic changes dif-
fer primarily in their stabilities and characteristic
timescales (both can be formulated probabilistically)
and their contributions to the cell states may be in-
tertwinned, the two physical levels, genetic and epi-
genetic, need not be viewed separately [34]. For ex-
ample, within the mathematical Markov model of the
cell-state dynamics, the probabilities of transitions
can be expressed by the elements of the transition
matrix, not regarding whether genetic or epigenetic.
Whether the epigenetic states are sufficiently stable
[49] (i. e. whether probabilities of the respective tran-
sitions are low enough) to enable Darwinian evolu-
tion of isogenic cells underpinned by purely epige-
netic states is an open question.
Evolutionarily Motivated Therapies. Cancer cells
continuously evolve their ability to survive in time-
varying microenvironment (as exemplified by devel-
oping the resistance against eventual therapeutic in-
terventions). Consequently, to stay efficient, the ther-
apy must be appropriately modified as well, which
is typically arranged by the combination therapies
and/or appropriate scheduling schemes which make
attempts to solve this problem explicitly. In the strat-
egy of benign cell boosters Maley and Forrest pro-
posed firstly to increase the proliferation rate of the
benign cells sensitive to a cytotoxin intentionally and
then apply the toxin [50]. Similarly, Chen et al. de-
signed strategy of an ’evolutionary trap’ which selects
from a karyotypically divergent population the sub-
population with predictably drugable karyotypic fea-
ture [51]. In the evolutionary double bind strategy to
control cancer, Gatenby at al. exploit that the ther-
apy resistance requires costly phenotypic adaptation
that reduces the fitness of the respective cells [52]. It
has been shown recently that the proliferation of ma-
lignant cells can be decreased by the administration
of non (or minimally) cytotoxic ersatzdroges [53, 54]
thereby the cell’s resources are diverted from the pro-
liferation and invasion towards the efflux pump ac-
tivity, which, consequently, lowers the fraction of the
cells with developed drug efflux mechanisms in the
population [54]. During recent years, directed evo-
lution of oncolytic viruses has been investigated in
the virotherapy [55]. Instead of detailed knowledge
of the molecular aspects of the interaction between
the cancer cell and the virus, the approach exploits
evolutionary principles such as diversified popula-
tion of viral candidates which undergo purposefully
designed selection steps to direct evolution towards
an explicitly pre-defined goal. Usefulness of the ap-
proach was demonstrated by the adaptation of the
RNA virus to the cells in which the tumor suppres-
sor gene p53 had been inactivated [56].
3Virotherapy is a targeted anticancer strategy in which
genetically engineered strains of viruses replicate and
lyse tumor cells [57]. Unfortunately, due to evolution
of cancer cells the ultimate success of the treatment
remains elusive. We hypothesize that even if one ad-
mits evolution of the virus, its fitness does not suf-
ficiently reflect its ability to lyse cancer cells which,
consequently, vanishes. In our work, the therapy is
conceived as a self-sustaining evolutionary process in
dynamic fitness landscape [58–61] with cytotoxicity
of elementary therapies reflected in their respective
fitness, which could prevent (or reduce) its decrease
during eventual treatment.
II. MODEL
Evolutionary Causation of Toxicity. The ultimate
goal of cancer research is to design the therapy
which stays efficient against heterogeneous and con-
tinuously changing cancer cells with the minimum
harm to healthy cells. To implement the evolution-
ary paradigm into the therapy design, we construct
the therapy as a population of heterogeneous ’elemen-
tary’ therapies (a ’therapy species’) each of them al-
lowed to interact exclusively with one of the avail-
able (therapy-free) cells (Fig. 1). Regarding the ther-
apeutic context, the principal feature of the elemen-
tary therapy is its toxicity to cells. To undergo contin-
uous, self-sustaining adaptation by the evolutionary
process, toxicity of the elementary therapy must play
the role of the therapy’s fitness, which means that it
must conform to evolutionary causation.
Firstly toxicity of the elementary therapy must result
from the real selection pressure, which means that the
elementary therapy must be put into interaction with
the cell. Secondly the evolutionary causation requires
that during the treatment the fundamental evolution-
ary principles, phenotypic variation, differential fit-
ness and heritability of fitness [62], apply. It follows
that i) the elementary therapies differ in their respec-
tive toxicities, ii) themore toxic elementary therapy is,
the more often it is applied, and, iii) repeated applica-
tion of the same elementary therapy provides toxicity
similar to that in its previous (i. e. ’parent’) applica-
tion, even if it is slightly changed (’mutated’). While
the points i) and iii) are straightforward and can be
ensured by the appropriate heterogeneity of the ele-
mentary therapies, the point ii) is less intuitive and
below we outline its minimalistic in silico implemen-
tation (Fig. 1).
In here proposed approach, each elementary therapy
may create complex with one of the therapy-free cells.
The elementary therapy can create the new complex
with another therapy-free cell only after its current
complex has decayed, playing the role of a catalyst.
It follows that each cell-therapy complex is exposed,
at the same time, to two counteracting selection pres-
FIG. 1: How toxicity turns into fitness. The red elementary
therapy kills the cell sooner than the blue one therefore it can be
applied more often. It means that the toxicity plays the role of
reproduction fitness. If the therapy is not toxic, it stays within
the complex and enables binding opportunity to free (i. e. more
toxic) therapies.
sures. On the one hand, the fitness of the cell is pro-
portional to the number of its copies, therefore longer
lifetime of the complex (hence the resistance to ther-
apy) is supported by the evolution of the target cell
population. On the other hand, the complexes are un-
der selection pressure due to the evolution of thera-
pies; the sooner the elementary therapy kills the cells
within its consecutive complexes, the higher is the
number of its repetitions (hence, by definition, its re-
production fitness). Consequently, shorter lifetime of
the complex (hence higher toxicity of the elementary
therapies) is implicitly supported by the evolution of
therapies. Despite the two evolutionary processes dif-
fer in their respective reproduction mechanisms, the
former creating physical copies (cells), the latter re-
peating the therapies accordingly to their respective
toxicities, the both processes satisfy one of the fun-
damental principles of evolution, the heritability of
fitness, which does not require any particular mecha-
nism of inheritance; only the correlation between the
parent’s and offspring’s fitness is required [62]. To
sum up, as in here proposed algorithm the number of
iterations of an elementary therapy (hence its fitness)
depends on the ability of the therapy to kill the cell,
the toxicity of the elementary therapy can be identi-
fied with its fitness.
To illustrate the above conceptual approach (Fig. 1),
we present in the following subsections its in silico
implementation. We have devised two ad hoc mod-
els, the conceptual model of the target cell popula-
tion and the model of a virtual elementary therapy
and its interaction with the cell within the complex.
4Feasibility of the respective algorithmic steps at bio-
chemical and biological levels is not considered; short
discussion about an eventual implementation of the
approach is provided in the Conclusions.
Model of the Target Cell Population. During a few
last decades many mathematical cancer models have
been constructed, mostly classified as (i) continuum,
formulated through differential equations, (ii) dis-
crete lattice models, usually represented by cellular
automata and, (iii) agent based with diverse levels
of ’intelligence’ assumed in the agents (for complete
review of mathematical cancer models, see [63–68]).
The respective types of models incorporate different
levels of biological punctuality focusing on different
scales, from microscopic to phenomenological. As in
carcinogenesis many biological phenomena run con-
currently, the multiscale models make an effort to
bridge the gap between the phenomenology and mi-
croscopic theory [69, 70]. Evolutionary models of can-
cer do not typically focus on the microscales. The
reason is that the phenotypes of cancer and normal
cells can have many alternative genetic (and epige-
netic) causes. Instead, evolution of cancer is driven by
the environmental selection forces that interact with
individual cellular strategies (or phenotypes) [19]. In
this way, the evolutionary models investigate how se-
lection pressure influence the life history characteris-
tics, such as survival strategy, reproduction behavior,
population heterogeneity, etc. [71–74].
The ad hoc choice of the genome-coded actions in our
coarse-grained model of the cell reflects here adopted
epitomization of target cells by cancer cells. As avoid-
ing programmed cell death (apoptosis) is one of the
hallmarks of cancer [75] no gene for it is assumed in
the above set of actions; target cells die due to the lack
of resources or to the therapy. On the other hand, the
dormancy and phenotypic switching are included as
they are often referred as possible alternative ways of
drug resistance. As a result each target cell is defined
by its state, φ ∈ {0,1}, enabling to quantify the impact
of an elementary therapy on the cell, see below, and
its ’genome’ consisting of L genes gj ∈ {R,M,S,D}, j =
1 . . . L, each representing specific cell-related action.
The tuple G ≡ 〈LR/L,LM /L,LS /L,LD /L〉, Lx being the
number of gene x in the genome, is introduced to ex-
press proportions of the respective genes in the cell’s
genome. The actions associated with the respective
genes correspond to: (R)eplication: the copy of the
cell is created, unless the lack of resources prevents
it, in which case the cell itself dies; if successful, the
copy (‘child’) inherits the parent’s genome and state
and undergoes mutation, (M)utation: the gene is se-
lected uniformly at random from the genome. If the
selected gene is ’M’, another gene selected uniformly
at random is replaced by the gene picked with the
same probability from {R,M,S,D}, (S)witching: the
cell state is switched either from 1 to 0 or from 0 to
1, depending on the current state, and (D)ormancy:
no action is performed. Proportions of the respective
gene in the genome of the cell determine its pheno-
type such as, for example, proliferative (abundance
of ’R’ genes), survival (abundance of ’D’ genes), the
cell state switching (’S’ gene) and genetically unstable
(’M’ gene).
Model of the Elementary Therapy. In our model, a
unified, biochemically reasoned therapy is replaced
by the ‘therapy species’, which is evolving population
of heterogeneous elementary therapies. Conceptual
novelty of the approach (Fig. 1) consists in avoiding
the necessity to specify explicitly the differences be-
tween cancer and normal cells, which is, due to intra-
tumor heterogeneity, the principal obstacle in com-
mon treatments. Instead, it is required that the model
of elementary therapy introduces variability in the
cells’ survival. It follows that to prevent ’premature
convergence’ (hence genetic drift) the population of
elementary therapies must start as less (or non)toxic.
To facilitate the instructive in silico modeling, the
elementary therapies are of the same mathematical
structure based on two characteristics - the rate of
change and the selectivity. These were chosen because
they obviously influence the fate of the target cell as
defined above, hence they guarantee the variability of
the fitness within the population of elementary thera-
pies. Nevertheless, in the eventual applications much
less intuitive characteristics can be chosen, based on
different pharmacological mechanisms of action.
The elementary therapy integrates all factors that ef-
fect the cell’s fate into one time-dependent variable
E(t), chosen to change continuously between 0 and 1
accordingly
E(t) =
1± sin(t/T )
2
, (1)
2piT being the period of the respective therapy. The
choice of the +/− sign is arbitrary, nevertheless once
chosen the sign persists during simulation.
To quantify selectivity of the therapy, S , the threshold
σ is defined as
σ =
1
1+ eS (|E(t)−φ|−C)
, (2)
where C = 0.5 postulates the symmetry of E(t) regard-
ing the two possible cell states. In the next, we denote
the therapy as the tuple D ≡ 〈T ,S〉.
The threshold σ determines the fate of the cell, apply-
ing the rule
action =



cell death, if υrand >σ,
,
selected uniformly at random
from the genome, otherwise
(3)
where υrand ∈ (0,1) is uniformly distributed random
number. Interaction of the therapy with the cell
5(Eqs. 1 to 3) applies only if the action selected in
Eq. (3) is the replication.
We emphasize that in the model the cell’s resistance
is not bound to a specific cell state φ but it is rather
viewed as the ability of the cell(s) to survive under an
instant therapy. For convenience, the cell in the state
φ closer to E(t) is assigned with lower probability of
death (Eqs. 2, 3). Regarding here followed therapeu-
tic context it is viewed as resistant, while the cell in
the complementary state (farther from the E(t), higher
probability of death) is referred as sensitive. Taking
into account the time variability of the therapy (Eq. 1)
it follows that the cell can be resistant in one moment
and sensitive in the other without switching its state.
Simulation Scheme. The simulation begins with the
population of N cells characterized by their genomes
Gi and states φi , i = 1 . . .N, evolving simultaneously
with the heterogeneous population of K therapies
Dk ≡ 〈Tk , Sk〉, k = 1 . . . K, (Eqs. 1, 2). Each genome
Gi , i = 1 . . .N, consists of L genes gj , j = 1 . . . L, selected,
at the beginning, uniformly at random from {R,M}.
The states φi , i = 1 . . .N are picked from {0,1}with the
same probability. The therapy species is represented
by K elementary therapies Dk = 〈Tk ,Sk〉, k = 1 . . .K,
each of them with its own period 2piTk and selectivity
Sk , starting as
Tk = 10
ξ and Sk = 10
η , k = 1 . . .K, (4)
where ξ ∈ (ξmin,ξmax) and η ∈ (ηmin,ηmax) are uni-
formly distributed random numbers.
During simulation, the cells and therapies evolve ac-
cordingly to the model (Eqs. 1-3). The number of
cells varies as implied by their interaction with el-
ementary therapies and the population carrying ca-
pacity provided by the system resources. At replica-
tion, the newly born cell inherits its state and genome
from its parent, and the both genomes undergo the
above described mutation procedure. In addition, the
offspring cell creates exclusive lifetime complex with
one of the free elementary therapies. In contrast to
the variable size of the population of cells, the size of
the therapy species is kept constant; elementary ther-
apies neither replicate, nor die; they only mutate ev-
ery time when they form the complex with the cell;
the mutated therapies are obtained as
T newk = T
old
k × 10
δ1 and Snewk = S
old
k × 10
δ2 , (5)
where δ1,δ2 ∈ (0,0.1) are uniformly distributed ran-
dom numbers. Subsequently, the values of parame-
ters within required intervals are guaranteed by im-
posing the limits as
X˜ =



X × 10γmax−γmin , for X < 10γmin ,
X × 10γmin−γmax , for X > 10γmax ,
X, otherwise
(6)
where X stands for T newk or S
new
k and γ for the respec-
tive ξ or η in Eq. 4.
During its lifetime, the cell repeatedly chooses uni-
formly at random the gene from its genome and per-
forms the respective actions. If the action is replica-
tion, the interaction of the cell and its respective ele-
mentary therapy is recalculated (Eqs. 1- 3). If the cell
survives, it replicates. When the cell dies, either due
to the interaction with the therapy or due to the lack
of resources at the moment of replication, its respec-
tive complex decays and the relinquished elementary
therapy becomes capable to create complex with an-
other newly born cell, playing the role of a catalyst.
III. RESULTS
Here, the cell state dynamics is represented by the de-
pendence of the ratio N1/N on the variable E(t); N1
and N are numbers of the cells in the state φ = 1 and
the target cell population size, respectively. Due to
fundamentally different physical implementation of
the model system, with biological time scales and car-
rying capacity substituted by the CPU and memory
limits (see Appendix), numerical values of T and S
in the figures below lack biological meaning and are
used only to outline a few typical behaviors of the
model. Despite that, some results, such as the de-
pendence of the cell state dynamics on the relations
between some of the parameters could have universal
meaning. In the subsections C and D, E(t) (Eq. 1) was
calculated for each cell-therapy complex separately,
with time t corresponding to the cell’s age expressed
as the CPU time consumed by the cell’s thread (run-
ning in parallel with other threads, see Appendix) in-
stead of simulation (i. e. ’physical’) time, providing
E(0) = 0.5 at the cell’s birth. Consequently, the ranges
of T of elementary therapies chosen in the Results
sections A and B differ in orders of magnitude from
those in sections C and D.
To get deeper insight into below in silico investiga-
tion of the evolutionary dynamics of the cells and ele-
mentary therapies, we have firstly studied a few cases
of the cell state dynamics where at least one popula-
tion, cells or therapies, was kept homogeneous (i. e.
isogenic or unified, respectively) and did not evolve.
Though most of presented features are rather obvious
by intuition, for the readers’ convenience we point out
the most dominant of them.
A. Isogenic target cell population under unified therapy
Firstly dependences of the cell state dynamics on the
three model characteristics, selectivity and period of
the unified therapy and the cell’s switching rate (LS /L
in Giso), were investigated. Fig. 2 shows convergence
of the (N1/N,E) trajectories for the respective combi-
nations of the above three model characteristics. The
three nonevolving isogenic target cell populations
which differ each other in the cells’ switching rates,
i) no switching, Giso = 〈0.5,0,0,0.5〉, ii) low switch-
6ing, Giso = 〈0.5,0,0.02,0.48〉, and iii) high switching,
Giso = 〈0.5,0,0.5,0〉, were exposed one by one to 8
different unified therapies Duni = 〈T ,S〉, combining
a few different periods 2piT (T = 400,100,40,10 ms)
and selectivities (S = 1,30). We note that to satisfy
the genome’s constraint (LR + LM + LS + LD)/L = 1, the
change in the switching rate LS /L is compensated by
the respective change of the probability of dormancy,
LD /L. Nevertheless, taking into account minor role of
the dormancy within our illustrative model, we omit
analysis of this step. Isogenic populations consisted
of a few thousands non-evolving cells in the states
φi , i = 1 . . .N, each picked from {0,1} with the same
probability.
FIG. 2: Examples of the cell state dynamics of non-evolving populations of isogenic cells which differ by the probability of the cell
state switching - no switching, low (LS /L = 0.02) and high (LS /L = 0.5) switching probability; for each of the populations two kinds
of therapies are applied - low and highly selective, respectively, quantified by the values of the parameter S = 1 and 30, respectively.
Moreover, for all the cases four unified therapies differing in their respective periods are applied, as quantified by the values of the
parameter T = 400,100,40 and 10 ms in (1). In each plot two series corresponding to the plus (red) or minus (black) sign in Eq. (1)
are depicted.
7In the case without switching, Giso = 〈0.5,0,0,0.5〉, the
population becomes extinct if the period 2piT is too
long (T = 400 ms in Figs. 2A, 2B, 3A, and 3B)
for the survival of the sensitive cells. The probabil-
ity of extinction increases with higher selectivity of
the therapy (Figs. 3A and 3B). In the case of low se-
lectivity, S = 1.0, and the shortest investigated pe-
riod given by T = 10 ms, the ability to switch the
cell state does not affect the cell state dynamics sig-
nificantly (Fig. 2A to C). However, high selectivity,
S = 30.0, can homogenize the cell states in the popu-
lation even during very short period without switch-
ing (Fig. 2B, T = 10 ms). Between the two limiting
periods, corresponding to T = 400 ms and T = 10 ms,
respectively, the population does not become extinct
and converges to one of the two cell states. When the
phenotype switching is allowed, the typical hysteretic
behavior of the cell state dynamics emerges for the se-
lectivity S = 30 (Figs. 2D and 2F, the period given by
T = 400ms) with the width of hysteretic loop decreas-
ing with the switching probability. It is obvious that
the similar cell state dynamics can be produced alter-
natively (Figs. 2C, T = 400 ms and 2F, T = 100 ms),
which indicates dependence of the cell state dynam-
ics on a scaling form constructed between selectivity,
period and the rate of switching.
We note that the relation between hysteresis and phe-
notype switching in evolutionary systems has often
been observed and studied [76]. It was shown in
bacteria that some antibiotics can induce long-lasting
changes in their physiology, termed cellular hystere-
sis, that influence bactericidal activity of other antibi-
otics and can be exploited to optimize antibiotic ther-
apy [77]. However, keeping in mind ad hoc choice
of the model aimed in particular to provide formal
fitness landscapes for here investigated purposes, we
leave deeper analysis of the specific hysteretic behav-
ior (or the memory effects caused by the therapy) of
the cell state dynamics and, eventually, the scaling
properties to future research.
FIG. 3: Dependence of the target cell population size on the period and selectivity of the therapy and the rate of switching of isogenic
cells. Obviously, under higher selectivity the system follows dynamics of E(t) unless too short period (here, corresponding to the case
T = 10 ms).
B. Evolving target cell population under unified therapy
In this subsection, the target cell population (for
its initialization see simulation scheme in Section II)
evolves under a few unified therapies Duni = 〈T ,S〉
which differ by their periods 2piT and selectivities S .
In the case of short periods, here corresponding to
Duni = 〈1,1〉 and 〈1,30〉, the switching probabilities
LS /L in the population converged to 0.02 (Figs. 4A,B),
which is the lowest possible nonzero value within the
model resolution. In the case of long periods, cor-
responding to the unified therapies Duni = 〈100,1〉
and 〈100,30〉, no switching has evolved (Figs. 4E to
F). When the therapies with intermediate periods,
Duni = 〈10,1〉 and 〈10,30〉, are applied, higher se-
lectivity makes population more state homogeneous
and, at the same time, decreases switching probabili-
ties (Figs. 4C, D).
In the previous subsection we demonstrated sensitiv-
ity of the cell state dynamics on the period 2piT and
the selectivity S of the therapy as implemented in the
model (Eqs. 1-6) as well as on the switching proba-
bility. In this subsection the interplay between the
period 2piT and selectivity S of the therapy and the
evolution of switching probability was shown in more
depth and the consequences of evolving it (or not) for
the cell state dynamics.
The results presented in this and the previous sub-
sections are very general and reflect simplicity of the
8above ad hocmodels. To obtain biologically more rele-
vant outcome, biologically realistic timescales for the
replication, phenotypic switching, apoptosis, carry-
ing capacity, etc, would be needed. Nevertheless, re-
garding the context of our work we require the capa-
bility of the model to generate sufficient variability of
the cell state dynamics, which has been demonstrated.
FIG. 4: Evolution of the switching rate under 6 different unified
therapies Duni = 〈T ,S〉, where the short period therapy uses
T = 1s, intermediate T = 10s, and the long period therapy T =
100s. The sizes of the target cell population and the switching
rates in the genome after the population becomes isogenic are
rescaled to emphasize dependences of the respective series on the
variable E(t). Population size counts the both cell states, 0 and
1; however, at the E(t) extrema one of the states (alternately)
dominates.
C. Isogenic target cell population under evolving therapy
Here, the relation between toxicities of the elementary
therapies and their fitness was investigated. Toxicity
of the elementary therapy is represented by the aver-
age lifetime of the cells which have applied it, and the
fitness of the therapy corresponds to the number of
its iterations, i. e. its abundance within the space of
all possible elementary therapies spanned by the in-
tervals (ξmin,ξmax)× (ηmin,ηmax) (Eq. 4).
In simulations, the therapy species consisting of K =
32768 elementary therapies Dk = 〈Tk ,Sk〉, k = 1 . . .K ,
evolves in interaction with non-evolving isogenic
populations (4 populations with different switch-
ing probabilities were one by one tested, Giso =
〈0.5,0,0,0.5〉, 〈0.5,0,0.02,0.48〉, 〈0.5,0,0.2,0.3〉 and
〈0.5,0,0.5,0〉). At the beginning, the cell states φi , i =
1 . . .N , were picked from {0,1} with the same prob-
ability and the elementary therapies’ parameters Tk
and Sk , k = 1 . . .K , determining the periods and selec-
tivities of the respective elementary therapies (Eq. 2),
were generated accordingly to Eq. 4 for ξ ∈ (2,9) and
η ∈ (0,3). The new (’mutated’) elementary therapies
were obtained from Eq. 5 imposing the boundary con-
ditions (Eq. 6) with δ1,δ2 ∈ (0,0.1).
The simulation results show that increase of the
switching probabilities in isogenic target cell popula-
tions makes the distributions of average lifetimes, as
well as the density of the therapy space, flatter (Fig. 5).
The average lifetimes of the cells under evolving ther-
apies presented in Figs. 5 and 6 were ≈ 52µs for Giso =
〈0.5,0,0,0.5〉, ≈ 52µs for Giso = 〈0.5,0,0.02,0.48〉, ≈
46µs for Giso = 〈0.5,0,0.2,0.3〉 and ≈ 39µs for Giso =
〈0.5,0,0.5,0〉.
FIG. 5: The average lifetimes of the cells (upper surfaces) which
apply the same elementary therapy versus number of its applica-
tions (expressed as the density of the discretized (ξmin,ξmax)×
(ηmin ,ηmax) therapy space, bottom surfaces, a. u. standing for
arbitrary units). The plots A to D show the results for 4 isogenic
target populations Giso which differ in switching probabilities.
The surfaces corresponding to the density of therapy space are
rescaled for the demonstration purposes; the heat maps of the
respective densities of the therapy space (bottom surfaces) are
shown more precisely in Fig. 6A to D.
The main result of this subsection (Figs. 5, 6) is that
less toxic elementary therapies (conferring to cells
longer average lifetimes) become less abundant in the
therapy species. Moreover, the flatness of the distri-
bution and the average lifetime of the cells depend on
the switching probability encoded in the genomes.
9FIG. 6: The heat maps show more precisely the density of the
therapy space for the corresponding populations in Fig. 5. Col-
ors of the heat maps are scaled to sharpen positions of the ex-
trema in the surfaces.
D. Evolving target cell population under evolving therapy
Here, the population of therapies evolves simultane-
ously with the population of cells. Dependence of
the average lifetimes of the cells on applied thera-
pies, specified by the parameters T and S , was in-
vestigated. As the density of the therapy space is
recorded after the population of target cells has con-
verged to isogenic (Giso = 〈0.6,0,0,0.4〉) the differences
in the cells’ lifetimes are attributed exclusively to the
applied therapies. Evolved switching probability was
0, which is consistent with the findings in the previ-
ous subsection that, in this specific case, the absence
of switching increases the average lifetime of cells.
Fig. 7 shows that the therapies conferring, on average,
longer lifetimes to the respective cells are underrep-
resented in the therapy species and vice versa.
The explanation of the anticorrelation is straightfor-
ward. Each cell, at its birth, creates the exclusive
complex with one of the available elementary thera-
pies (which ’mutates’). Even neither in the case of
long living cell (dormant cell or the cell resistant to its
respective therapy) is the therapy replaced. It might
seem (therapeutically) contraproductive, as it contra-
dicts to an intuitive expectation that the resistant cells
should be the primary target of therapies, as resist-
ing the cell death is one of the hallmarks of cancer
cells [75]. As it was discussed above, here the fitness
of the therapy corresponds to the number of its iter-
ations (instead of the number of its physical copies).
Straightforwardly, the therapeutic effort is to arrange
that more fit (toxic) elementary therapies are applied
more often, and vice versa, if the therapy is not effi-
cient, it should be repeated only rarely (to preserve
the exploration capability of the algorithm). The anti-
correlation in Fig. 7 implies that the less efficient ther-
apy is, the less often it is used, which is the desired re-
sult. The message is that if it is not possible to deter-
mine a priori which therapy is the best (and to apply
it), one should eliminate less fit therapies (to increase
the abundance of the more toxic ones).
FIG. 7: Comparison of the average lifetimes of the cells which
applied the same elementary therapy (upper surface in plot A)
with the density of the space of elementary therapies (bottom
surface in A, a.u. standing for the arbitrary units). As the den-
sity of the therapy space is recorded after the population has
converged to isogenic (Giso = 〈0.6,0,0,0.4〉), the average life-
times depend only on the respective elementary therapies. The
corresponding heat maps B, C underline the correlation of the
area of the above-average lifetimes (bright yellow area in plots
A, B) with sparsely populated areas in the therapy space (deep
violet area in plots A, C).
IV. DISCUSSION
In here presented scenario, the resistant cells implic-
itly serve as inhibitors for non (or less) efficient ther-
apies. By this way, the resistant cells direct the evolu-
tion of the therapy species to more efficient therapies.
Here, it is required that the elementary therapy can
create complex with the next therapy-free cell only af-
ter its current cell’s death. By this, toxicity of the ther-
apy is connected with its fitness in the evolution con-
forming way. However, this requirement disregards
that many cancers evolve multidrug resistance by up-
regulating membrane efflux pump that exports drugs,
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thereby ensuring the cell’s survival. As in this case
the therapy is pumped out before it can fully exhibit
its particular properties (primarily its toxicity), evo-
lution of elementary therapies becomes questionable
as one of the crucial evolutionary principle, the dif-
ferential fitness [62], is significantly suppressed. On
the other hand, the efflux pump comes with the en-
ergetic cost [78] which makes the cells with the efflux
pump less fit than those without it when the therapy
is absent (or nontoxic [53, 54]).
In here presented conceptualization, the therapies are
heterogeneous, each of them interacting with the cells
with heterogeneous properties, including the differ-
ences in their sensitivity to different therapies. If the
cell pumps out the therapies not regarding their re-
spective toxicities, it wastes resources and becomes
less fit. Therefore, we speculate that in reality the
cells would evolve mechanism(s) enabling them to ex-
trude therapies reflecting the level of their respective
toxicity. If true, more toxic therapies prevail in popu-
lation, just as in here investigated case when the death
of the cell was required to re-apply its therapy by the
next cell. It would mean that the toxicity plays, from
the evolutionary viewpoint, the role of the fitness of
the therapy no matter whether it shortens the cell’s
lifetime, or redirects the cell’s resources from replica-
tion and invasion to building efflux mechanism(s).
In here presented algorithm, each newly born cell cre-
ates the complex with the therapy which is, in gen-
eral, different from the therapy of its parent. It fol-
lows, that even if the offspring has inherited resis-
tance against the therapy of its parent, it might still
be sensitive to its own, in addition mutated, ther-
apy, which obviously decreases its (as well as its par-
ent’s) fitness. This effect might be more pronounced
in the case of cells with unlimited replicative poten-
tial, which is one of the cancer hallmarks [79]. This
adds more biological flavor to the model, as most
chemotherapeutic drugs are designed to effectively
target fast-dividing cells.
V. CONCLUSIONS
In the paper, a unified therapy is substituted by the
therapy species, the evolving constant size population
of heterogeneous elementary therapies, each of them
with the fitness resulting a posteriori from its interac-
tion with the cells and vice versa. In this way, not only
the therapies govern the evolution of different pheno-
types, but the variable resistances of the cells govern
the evolution of the therapies as well. From the view-
point of evolving elementary therapies, evolving pop-
ulation of target cells plays the role of dynamical en-
vironment. As the therapies themselves mutate, less
dense areas of the therapy space are repeatedly repop-
ulated by diffusion, retaining exploratory power of al-
gorithm. Our in silico investigation indicates that the
algorithm can identify the most efficient therapies by
inhibiting those which are less efficient (as evidenced
by their lower ability to kill the host cell). Not be-
ing tailored to some specific molecular mechanisms
responsible for the respective cancerous features, the
approach could, in principle, to cope with intratumor
heterogeneity and stay efficient during adaptation of
cancer cells to changed therapy.
Despite conceptual simplicity of the above approach
we foresee a number of technical difficulties in its
eventual therapeutic implementation. The ultimate
question, i. e. which species will be the winner of the
evolutionary ’arms race’ - cancer or therapy - stays
therefore unanswered in our paper. Each evolution-
ary process samples its respective search space with
some specific efficiency. While the efficiency of the
sampling by cancer cells population results from their
biochemistry, in the case of the therapy species the ef-
ficiency of sampling would derive from its eventual
therapeutic realization. The questions follow: What
agent could be used as the replication-deficient ther-
apy species? Must it be organic at all? How to mu-
tate the therapies? How to deliver the elementary
therapy into the cell, and, subsequently, to avoid the
efflux pump, etc. Some of the above issues are om-
nipresent in cancer research and are intensively stud-
ied. Important insights could be gained from the vi-
rotherapy where the evolutionary principles are used
to direct evolution towards the explicitly pre-defined
goal, and the virus-based gene-therapy which uses the
replication-deficient viruses as vectors.
Recently, the framework for classifying tumors ac-
cording to their evolvability was presented [74], based
on the diversity of neoplastic cells and its changes
over time (constituting the Evo-index) on the one
hand, and the environmental hazard and availabil-
ity of resources (Eco-index) on the other hand. The
authors of the above paper envision that in the fu-
ture, the classification could indicate how the tumor
of the respective type of evolvability would change
with different therapy, helping so clinicians to choose
the interventions regarding evolvability of the respec-
tive neoplasms. Our work enables to study the inter-
play between related characteristics, such as the phe-
notype switching and mutability, which reflect diver-
sity of the target cell population and its changes over
time and could eventually play the role of the Evo-
index. Similarly, the environmental hazard is in our
work represented by the selectivity of the therapy.
The resources are implicitly (and, in principle, un-
avoidably) included in the model. Variability of the
selection pressure is mediated by the different peri-
ods of elementary therapies. Owing to this we believe
that here presented approach could contribute to bet-
ter understanding of the relation between evolvabil-
ity of cancer and dynamics of environment (hence the
therapy).
In his iconoclastic paper [80], Leonard Adleman pro-
posed that computationally hard problems, such as
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therein presented NP-complete directed Hamiltonian
path problem, can be efficiently solved with the algo-
rithmic steps realized by the standard tools of molec-
ular biology. We hope that here speculated possible
benefits of yet conceptual approach could, perhaps,
motivate cancer researchers to test its feasibility in a
therapeutically relevant way.
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APPENDIX
The program encoding the above model conforms to
the POSIX Threads execution scheme with the round-
robin time sharing as implemented in the Linux pro-
gramming interface API [81], enabling to execute
the respective cells concurrently as separate threads.
More important than an eventual CPU gain, accruing
from the program parallelism, is the benefit from del-
egating some of the model’s parameters to the respec-
tive system CPU andmemory resources. For example,
the size of the cell population derives, apart from the
cells’ genomes themselves, from the maximum num-
ber of concurrently running threads allowed by the
system (representing ‘carrying capacity’ of the pop-
ulation), duration of the thread creation (being the
counterpart of the cell replication), size of the thread
stack, etc. Owing to the implicit substitution of some
model parameters by the system parameters, the im-
plementation of the model is more robust, simpler
and enable to concentrate on particular biologically
relevant aspects, such as demonstrated by the above
results. Obviously, the hardware constraints can be
viewed as the counterpart of the constraints implied
by biochemistry which are always present in biologi-
cal experiments.
Our specific hardware restrictions, such as the max-
imum allowed concurrently running threads in the
system, duration of the thread creation (hundreds of
nanoseconds) and cancellation processes, etc, enabled
us to simulate populations close to maximum size
N ≈ 10000, Fig. 3. In summary, between 107 and
108 (≈ 104 per second) cell-therapy complexes could
be tested in a 1-hour simulation. The number of ele-
mentary therapies in the therapy species during sim-
ulations was kept constant (K = 32768), reflecting the
particular hardware implementation.
